{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:44:14Z","timestamp":1788871454773,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Otsuka Pharmaceutical Development & Commercialization Inc"},{"name":"Otsuka Pharmaceutical Co Ltd"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1053\/j.ajkd.2010.11.029","type":"journal-article","created":{"date-parts":[[2011,2,19]],"date-time":"2011-02-19T05:16:02Z","timestamp":1298092562000},"page":"692-699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study"],"prefix":"10.1053","volume":"57","clinical-trial-number":[{"clinical-trial-number":"nct00428948","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vicente E.","family":"Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyongtae T.","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Devuyst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared J.","family":"Grantham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly B.","family":"Krasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2010.11.029_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0092-8674(95)90339-9","article-title":"Polycystic kidney disease: the complete structure of the PKD1 gene and its protein","volume":"81","year":"1995","journal-title":"Cell"},{"key":"10.1053\/j.ajkd.2010.11.029_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1293-359","article-title":"Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease","volume":"5","author":"Peters","year":"1993","journal-title":"Nat Genet"},{"key":"10.1053\/j.ajkd.2010.11.029_bib3","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2010.11.029_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2010.11.029_bib5","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2010.11.029_bib6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1681\/ASN.2007020155","article-title":"Autosomal dominant polycystic kidney disease: time for a change?","volume":"18","author":"Chapman","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2010.11.029_bib7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1046\/j.1523-1755.2003.00242.x","article-title":"Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease","volume":"64","author":"Grantham","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2010.11.029_bib8","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2010.11.029_bib9","doi-asserted-by":"crossref","first-page":"F1166","DOI":"10.1152\/ajprenal.00196.2007","article-title":"Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL","volume":"293","author":"Mutig","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ajkd.2010.11.029_bib10","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1523-1755.2005.00703.x","article-title":"Vasopressin antagonists in polycystic kidney disease","volume":"68","author":"Torres","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2010.11.029_bib11","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2010.11.029_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2010.11.029_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.0954-6820.1986.tb03330.x","article-title":"Expansion of extracellular volume in early polycystic kidney disease","volume":"219","author":"Danielsen","year":"1986","journal-title":"Acta Med Scand"},{"key":"10.1053\/j.ajkd.2010.11.029_bib14","first-page":"329","article-title":"[The effect of hypervolemia on electrolyte level and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease]","volume":"96","author":"Michalski","year":"1996","journal-title":"Pol Arch Med Wewn"},{"key":"10.1053\/j.ajkd.2010.11.029_bib15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2010.11.029_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2010.11.029_bib17","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2010.11.029_bib18","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2010.11.029_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2010.11.029_bib20","first-page":"68A","article-title":"A phase IIB pilot study of the safety and efficacy of tolvaptan, a vasopressin V2 receptor antagonist (V2RA) in patients with ADPKD [abstract]","volume":"16","author":"Chapman","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2010.11.029_bib21","first-page":"497A","article-title":"Phase 2 open-label study to determine long-term safety, tolerability and efficacy of split-dose tolvaptan in ADPKD [abstract]","volume":"20","author":"Torres","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2010.11.029_bib22","first-page":"746A","article-title":"An open-label long-term administration study of tolvaptan in patients with ADPKD in Japan [abstract]","volume":"20","author":"Higashihara","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2010.11.029_bib23","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2010.11.029_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2010.11.029_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/sim.4780090414","article-title":"The power to detect differences in average rates of change in longitudinal studies","volume":"9","author":"Lefante","year":"1990","journal-title":"Stat Med"},{"key":"10.1053\/j.ajkd.2010.11.029_bib26","series-title":"Modeling Survival Data, Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"10.1053\/j.ajkd.2010.11.029_bib27","series-title":"SAS\/STAT software: changes and enhancements","year":"2001"},{"key":"10.1053\/j.ajkd.2010.11.029_bib28","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/00004728-200007000-00019","article-title":"Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease","volume":"24","author":"Bae","year":"2000","journal-title":"J Comput Assist Tomogr"},{"key":"10.1053\/j.ajkd.2010.11.029_bib29","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2010.11.029_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2008.558","article-title":"Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months","volume":"75","author":"Kistler","year":"2009","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2010.11.029_bib31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2010.11.029_bib32","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638610017841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638610017841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:57:09Z","timestamp":1759456629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638610017841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0272638610017841"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2010.11.029","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2010.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}